| COVID-19 Virus Disease
Olumiant vs Paxlovid
Side-by-side clinical, coverage, and cost comparison for covid-19 virus disease.Deep comparison between: Olumiant vs Paxlovid with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsPaxlovid has a higher rate of injection site reactions vs Olumiant based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Paxlovid but not Olumiant, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Olumiant
Paxlovid
At A Glance
Oral
Once daily
JAK inhibitor
Oral
Twice daily
SARS-CoV-2 main protease inhibitor
Indications
- Rheumatoid Arthritis
- COVID-19 Virus Disease
- Alopecia Areata
- COVID-19 Virus Disease
Dosing
Rheumatoid Arthritis 2 mg once daily orally, with or without food; may be used as monotherapy or in combination with methotrexate or other non-biologic DMARDs.
COVID-19 Virus Disease 4 mg once daily orally, with or without food, for 14 days or until hospital discharge, whichever occurs first.
Alopecia Areata 2 mg once daily orally; increase to 4 mg once daily if response is not adequate; reduce back to 2 mg once daily when adequate response is achieved.
COVID-19 Virus Disease 300 mg nirmatrelvir (two 150 mg tablets) with 100 mg ritonavir (one 100 mg tablet) taken together orally twice daily for 5 days, initiated within 5 days of symptom onset. For moderate renal impairment (eGFR >=30 to <60): 150 mg nirmatrelvir with 100 mg ritonavir twice daily for 5 days. For severe renal impairment (eGFR <30): 300 mg nirmatrelvir with 100 mg ritonavir once on Day 1, then 150 mg nirmatrelvir with 100 mg ritonavir once daily Days 2-5 (after hemodialysis on dialysis days).
Contraindications
—
- Clinically significant hypersensitivity reactions (toxic epidermal necrolysis or Stevens-Johnson syndrome) to nirmatrelvir, ritonavir, or any component
- Co-administration with CYP3A substrates with elevated concentrations associated with serious or life-threatening reactions: alfuzosin, ranolazine, amiodarone, dronedarone, flecainide, propafenone, quinidine, colchicine (in renal or hepatic impairment), lurasidone, pimozide, silodosin, eplerenone, ivabradine, dihydroergotamine, ergotamine, methylergonovine, lovastatin, simvastatin, voclosporin, lomitapide, eletriptan, ubrogepant, sildenafil for pulmonary arterial hypertension, triazolam, oral midazolam, flibanserin, tolvaptan, finerenone, naloxegol, suzetrigine
- Co-administration with strong CYP3A inducers (potential for loss of virologic response): apalutamide, enzalutamide, carbamazepine, phenobarbital, primidone, phenytoin, rifampin, rifapentine, lumacaftor/ivacaftor, St. John's Wort
Adverse Reactions
Most common (>=1%) Upper respiratory tract infections, nausea, herpes simplex, herpes zoster, acne, hyperlipidemia, urinary tract infections, headache, fatigue, folliculitis, lower respiratory tract infections, genital Candida infections, anemia, neutropenia, liver enzyme elevations, blood creatine phosphokinase increased, thrombocytosis, deep vein thrombosis, pulmonary embolism
Serious Serious infections, mortality, malignancy and lymphoproliferative disorders, major adverse cardiovascular events, thrombosis, hypersensitivity, gastrointestinal perforations, laboratory abnormalities
Postmarketing Drug hypersensitivity including rash, urticaria, and angioedema
Most common (>=1%) dysgeusia, diarrhea, vomiting
Postmarketing anaphylaxis, hypersensitivity reactions, toxic epidermal necrolysis, Stevens-Johnson syndrome, headache, hypertension, abdominal pain, nausea, malaise
Pharmacology
Baricitinib is a JAK inhibitor that selectively inhibits JAK1, JAK2, and TYK2, preventing phosphorylation and activation of STATs and thereby modulating cytokine signaling pathways involved in hematopoiesis and immune cell function.
Nirmatrelvir is a peptidomimetic inhibitor of the SARS-CoV-2 main protease (Mpro), preventing viral polyprotein processing and replication. Ritonavir inhibits CYP3A-mediated metabolism of nirmatrelvir, increasing its plasma concentrations.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Olumiant
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (1/12) · Qty limit (9/12)
Paxlovid
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Olumiant
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (6/8)
Paxlovid
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
Humana
Olumiant
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Paxlovid
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$25/momo
Olumiant Savings Card - Non-covered benefitCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availablePAF Co-Pay Relief: COVID-19 & Post COVID Conditions
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
OlumiantView full Olumiant profile
PaxlovidView full Paxlovid profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.